Metastatic Soft Tissue Sarcoma Clinical Trial
Official title:
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
OUTLINE: Patients receive itacitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 7 and 30 days, every 12 weeks from baseline for up to 1 year, and then every 6 months thereafter. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03793361 -
Phase II Study of Regorafenib as Maintenance Therapy
|
Phase 2 | |
| Completed |
NCT03009201 -
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
|
Phase 1 | |
| Withdrawn |
NCT03397186 -
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03965234 -
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04028063 -
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT04200443 -
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT01514188 -
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
| Completed |
NCT01574716 -
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
|
Phase 2 | |
| Completed |
NCT02500797 -
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT03138161 -
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03660930 -
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
|
Phase 1/Phase 2 |